You have 0 items in your cart
Medical Director, Texas Liver Care, and Director & Principal Investigator, Evidentis Clinical Research. Transplant hepatologist and obesity medicine specialist with a focus on alcohol-associated and metabolic liver disease.
Chief of Hepatology and Liver Transplantation at Baylor Scott & White and Medical Director of the Center for Advanced Liver Disease.
Professor of Medicine at Houston Methodist and Weill Cornell Medicine and internationally recognized expert in steatotic liver disease, clinical trials, and therapeutic development.
Medical Director of Research at the Clinical Research Institute of Ohio and internationally recognized expert in steatotic liver disease and clinical drug development.
Associate Professor of Medicine at Virginia Commonwealth University and Director of Alcohol Sciences at the Stravitz-Sanyal Institute, specializing in alcohol-associated and steatotic liver disease.
Internationally recognized hepatologist and transplant physician with expertise in liver transplantation, steatotic liver disease, and clinical drug development.
Assistant Professor of Internal Medicine at UT Southwestern and President of the Dallas Obesity Society, specializing in obesity medicine, metabolic health, and preventive care.
Transplant hepatologist at Baylor St. Luke’s Medical Center with expertise in liver transplantation, cirrhosis, viral hepatitis, and liver cancer.
Assistant Professor of Internal Medicine at UT Southwestern and transplant hepatologist specializing in advanced liver disease, with research focused on digital health and artificial intelligence.
Transplant hepatologist and gastroenterologist at Methodist Dallas Medical Center specializing in autoimmune and cholestatic liver disease, cirrhosis, and liver transplantation.
Associate Professor of Internal Medicine at UT Southwestern and transplant hepatologist specializing in advanced liver disease, viral hepatitis, and liver transplantation.
Endocrinologist at Baylor Scott & White Health specializing in diabetes, obesity, metabolism, and cardiovascular risk reduction.
Transplant hepatologist at Baylor Scott & White Health specializing in advanced liver disease, liver transplantation, and hepatocellular carcinoma.
Assistant Professor of Medicine at Western University and transplant hepatologist specializing in steatotic liver disease, liver transplantation, and cardiometabolic health.
Bariatric and minimally invasive surgeon at Baylor Scott & White Health specializing in metabolic and bariatric surgery, robotic surgery, and complex abdominal wall reconstruction.
Assistant Professor of Psychiatry at UT Southwestern and board-certified addiction psychiatrist specializing in alcohol and substance use disorders and complex psychiatric care.
Transplant hepatologist at Baylor Scott & White Health specializing in advanced liver disease, liver transplantation, and hepatobiliary malignancies.
Pediatric gastroenterology fellow at UT Southwestern, liver transplant recipient, and nationally recognized patient advocate bridging clinical medicine, research, and lived experience.
| Time | Program |
|---|---|
| 7:30 AM – 8:30 AM | Breakfast and RegistrationDelta Marriott Foyer |
| Session 1 – Integrating Metabolic Health in Liver Care | |
| 8:30 AM – 8:55 AM | Weight Management in Liver Disease: Diet, Activity, and Obesity PharmacotherapyTonia Vinton, MD |
| 8:55 AM – 9:20 AM | Endobariatrics & Bariatric Surgery in the GLP-1 Agonist EraMazen Iskander, MD |
| 9:20 AM – 9:45 AM | Practical Management Strategies for Diabetes, Hypertension, and Cardiovascular Risk ReductionScott Carlson, MD |
| 9:45 AM – 10:10 AM | Metabolic Health After Transplant: Preventing Weight Gain, Diabetes, and Cardiovascular DiseaseMohammad Qasim Khan, MD |
| 10:10 AM – 10:30 AM | Panel Discussion & Q&A |
| 10:30 AM – 10:45 AM | Break and Visit ExhibitsFoyer |
| 10:45 AM – 11:10 AM | Living the Journey: A Patient's Perspective on Liver DiseaseAhmad Anouti, MD |
| 11:10 AM – 12:40 PM | Lunch & Visit Exhibits
Delta Marriott Foyer
11:30 AM – 12:15 PM
Industry-Supported Symposium (Non-CME): Rezdiffra: Unlocking the Potential of a Liver-Directed Treatment
Ashwini Mehta, DO
Chisholm Ballroom III | Sponsored by Madrigal Pharmaceuticals
Non-CME |
| Session 2 – Steatotic Liver Disease – The Clinical Spectrum & Future Directions | |
| 12:40 PM – 1:05 PM | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Impact & Evolving ConceptsNaim Alkhouri, MD |
| 1:05 PM – 1:30 PM | Metabolic Dysfunction-Associated Alcohol-Related Liver Disease (MetALD): Defining the OverlapJuan Pablo Arab, MD |
| 1:30 PM – 1:55 PM | Alcohol Use Disorder and Disordered Eating in Liver Disease: Clinical Management StrategiesFabrizzio Delgado, MD |
| 1:55 PM – 2:20 PM | Steatotic Liver Disease Drug Pipeline: Current Trials and Future HorizonsMichael Charlton, MBBS |
| 2:20 PM – 2:45 PM | How I Treat MASLD and MetALD: A Practical, Case-Based ApproachMazen Noureddin, MD |
| 2:45 PM – 3:05 PM | Panel Discussion & Q&A |
| 3:05 PM – 3:20 PM | Break and Visit ExhibitsFoyer |
| Session 3 – General Hepatology Updates | |
| 3:20 PM – 3:40 PM | Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Diagnosis and Treatment UpdatesAshwini Mehta, DO |
| 3:40 PM – 4:00 PM | Hepatocellular Carcinoma and Cholangiocarcinoma: Advances in Diagnosis and ManagementCraig Rosenstengle, MD |
| 4:00 PM – 4:20 PM | Artificial Intelligence in Liver CareJeremy Louissaint, MD |
| 4:20 PM – 4:40 PM | Preventing Cirrhosis Complications: From Anticoagulation to Beta BlockersRanjeeta Bahirwani, MD |
| 4:40 PM – 5:00 PM | Viral Hepatitis in 2026: Practical Updates in Screening, HBV Management, and Cure PathwaysThomas Kerr, MD |
| 5:00 PM | Closing Remarks and Networking Reception |
